DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Palandri F, Palumbo GA, Elli EM. et al.
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Blood Cancer J 2021;
11 (01) 4
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.